1. Home
  2. PMAX vs PPCB Comparison

PMAX vs PPCB Comparison

Compare PMAX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$1.11

Market Cap

2.7M

Sector

N/A

ML Signal

HOLD

Logo Propanc Biopharma Inc.

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$1.16

Market Cap

2.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
PPCB
Founded
2019
2007
Country
Hong Kong
Australia
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.8M
IPO Year
2024
2011

Fundamental Metrics

Financial Performance
Metric
PMAX
PPCB
Price
$1.11
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.8K
120.1K
Earning Date
05-12-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.06
52 Week High
$5.20
$6.79

Technical Indicators

Market Signals
Indicator
PMAX
PPCB
Relative Strength Index (RSI) 27.66 41.61
Support Level $0.24 $0.74
Resistance Level $2.69 $1.26
Average True Range (ATR) 0.17 0.14
MACD -0.03 0.01
Stochastic Oscillator 11.66 24.62

Price Performance

Historical Comparison
PMAX
PPCB

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: